Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT01011933
- Phase
- PHASE2
- Status
- Completed
Conditions
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Recurrent Uterine Corpus Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Diagnostic Laboratory Biomarker Analysis — OTHERCorrelative studies
- Selumetinib — DRUGGiven PO
Study Details
This phase II trial is studying how well selumetinib works in treating patients with recurrent or persistent endometrial cancer that has come back or is persistent. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Key Dates
- Start date
- Sep 30, 2009
- Status verified
- Jul 2019
- Primary completion
- Jan 31, 2016
- Completion
- Jan 31, 2016
Study Design
- Enrollment
- 54 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (selumetinib)Patients receive selumetinib PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Blood and archived tumor tissue samples are collected for biomarker studies.
Primary Outcome Measure
Number of Participants With or Without Progression-free Survival for > 6 Months by Response Evaluation Criteria for Solid Tumors (RECIST) [ Time Frame: > 6 months from study entry ]
Locations (72)
Find similar trials in Los Angeles, CA
By research site
Los Angeles County-USC Medical Center· Los Angeles, CAUSC / Norris Comprehensive Cancer Center· Los Angeles, CAUniversity of Colorado Cancer Center - Anschutz Cancer Pavilion· Aurora, COHartford Hospital· Hartford, CTSmilow Cancer Hospital Care Center at Saint Francis· Hartford, CTThe Hospital of Central Connecticut· New Britain, CT
Related Studies
- Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial CancerPHASE3 · Recruiting · University of Utah · Palo Alto, California
- Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial CancersRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaPHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaPHASE3 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama